Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2007

Weitzel Jeffrey N, Buys Saundra S, Sherman William H, Daniels AnnaMarie, Ursin Giske, Daniels John R, MacDonald Deborah J, Blazer Kathleen R, Pike Malcolm C, Spicer Darcy V

Abstract excerpt

PURPOSE: Women with a BRCA1 mutation (BRCA1(mut)) need risk reduction options beyond mastectomy and oophorectomy. We evaluated the efficacy, safety, and tolerability of hormonal chemoprevention with a gonadotropin-releasing hormone agonist (GnRHA) with low-dose add-back steroids in BRCA1(mut) carriers. EXPERIMENTAL DESIGN: The 12-month open label clinical trial used the GnRHA deslorelin, ultra-low-dose estradiol...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticarcinogenic Agents
Share to Bone Density

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estradiol

Share to Gonadotropin-Releasing Hormone

Share to Mammography

Share to Quality of Life

Share to Steroids

Share to Testosterone

Source

Identifiers

PMID: 17255289
DOI: 10.1158/1078-0432.CCR-06-1902

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers.PMID 17255289Read ↗

Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk.Semantic proximity Read ↗

Hormonal management after risk-reducing surgery in BRCA-mutated triple-negative breast cancer survivors.Semantic proximity Read ↗

Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety.Semantic proximity Read ↗

Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey.Semantic proximity Read ↗

The management of sexuality, intimacy, and menopause symptoms (SIMS) after prophylactic bilateral salpingo-oophorectomy: How to maintain sexual health in "previvors".Semantic proximity Read ↗

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.Semantic proximity Read ↗

MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.Semantic proximity Read ↗

The management of menopausal symptoms in women following treatment for cancer at a specialist menopause service.Semantic proximity Read ↗

A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density.Semantic proximity Read ↗

High mammographic density is associated with an increase in stromal collagen and immune cells within the mammary epithelium.Semantic proximity Read ↗

Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years.Semantic proximity Read ↗

Impact of MRI surveillance and breast cancer detection in young women with BRCA mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.